Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Zura Bio in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio's Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.82) EPS.

Several other equities analysts have also recently weighed in on the company. Oppenheimer lowered their target price on Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, May 9th. Chardan Capital lowered their target price on Zura Bio from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, March 26th. Finally, Guggenheim reaffirmed a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Zura Bio presently has a consensus rating of "Buy" and an average target price of $14.33.

Zura Bio Stock Performance

ZURA traded down $0.02 during trading on Tuesday, reaching $1.02. The company had a trading volume of 293,130 shares, compared to its average volume of 410,534. Zura Bio has a 12-month low of $0.97 and a 12-month high of $5.56. The firm's 50-day simple moving average is $1.25 and its 200 day simple moving average is $1.86. The company has a market cap of $69.74 million, a price-to-earnings ratio of -1.46 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02).

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rhumbline Advisers grew its position in Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company's stock valued at $94,000 after acquiring an additional 10,231 shares during the period. Barclays PLC grew its holdings in shares of Zura Bio by 22.6% during the fourth quarter. Barclays PLC now owns 78,523 shares of the company's stock worth $197,000 after purchasing an additional 14,462 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Zura Bio by 12,060.8% during the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company's stock worth $6,583,000 after purchasing an additional 2,611,532 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Zura Bio by 102.1% during the fourth quarter. Renaissance Technologies LLC now owns 129,114 shares of the company's stock worth $323,000 after purchasing an additional 65,214 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Zura Bio by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company's stock worth $2,389,000 after purchasing an additional 42,801 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.